These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 14742815)

  • 1. Therapeutic and economic consequences of OTC loratadine.
    Nair KV; Sullivan PW
    Ann Pharmacother; 2004 Jan; 38(1):169-71. PubMed ID: 14742815
    [No Abstract]   [Full Text] [Related]  

  • 2. OTC loratadine.
    Med Lett Drugs Ther; 2003 Jan; 45(1147):3-4. PubMed ID: 12515952
    [No Abstract]   [Full Text] [Related]  

  • 3. Allergy warning.
    Underwood A
    Newsweek; 2002 Dec; 140(24):88. PubMed ID: 12500716
    [No Abstract]   [Full Text] [Related]  

  • 4. South Dakota Medicaid will now cover OTC Loratadine and OTC Prilosec.
    Brandenburg V; Darger D; Christianson H; Goeden G; Engelbrecht J; Hedge D; Holm R; Ladwig W;
    S D J Med; 2005 Jan; 58(1):17. PubMed ID: 15696732
    [No Abstract]   [Full Text] [Related]  

  • 5. The economic impact of payer policies after the Rx-to-OTC switch of second-generation antihistamines.
    Sullivan PW; Nichol MB
    Value Health; 2004; 7(4):402-12. PubMed ID: 15449632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coupon programs curb antihistamine utilization.
    Berberabe T
    Manag Care; 2003 Aug; 12(8):28-9. PubMed ID: 12966848
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy.
    Sullivan PW; Nair KV; Patel BV
    Am J Manag Care; 2005 Jun; 11(6):374-82. PubMed ID: 15974556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA approves OTC Claritin.
    FDA Consum; 2003; 37(1):3. PubMed ID: 12625285
    [No Abstract]   [Full Text] [Related]  

  • 9. Pros and cons of over-the-counter availability of histamine2-receptor antagonists.
    Feldman M
    Arch Intern Med; 1993 Nov; 153(21):2415-24. PubMed ID: 8105765
    [No Abstract]   [Full Text] [Related]  

  • 10. Patient, medicate thyself.
    Ortolon K
    Tex Med; 2003 Nov; 99(11):43-6. PubMed ID: 14650719
    [No Abstract]   [Full Text] [Related]  

  • 11. Switching prescription drugs to over the counter: consumers may benefit financially in examples from the US.
    Sullivan PW
    BMJ; 2005 Apr; 330(7496):904-5. PubMed ID: 15831881
    [No Abstract]   [Full Text] [Related]  

  • 12. Switching the histamine H2 receptor antagonist famotidine to nonprescription status in Canada. An economic evaluation.
    Tasch RF; Goeree R; Henke CJ; O'Brien BJ
    Pharmacoeconomics; 1996 Jan; 9(1):61-75. PubMed ID: 10160088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Policy analysis of the conversion of histamine2 antagonists to over-the-counter use.
    Kalish SC; Bohn RL; Avorn J
    Med Care; 1997 Jan; 35(1):32-48. PubMed ID: 8998201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA panel recommends OTC status for second-generation antihistamines.
    Rollins G
    Ann Allergy Asthma Immunol; 2001 Jul; 87(1):3-5. PubMed ID: 11476458
    [No Abstract]   [Full Text] [Related]  

  • 15. OTC product: Loratadine for urticaria.
    Pray WS
    J Am Pharm Assoc (2003); 2005; 45(1):112. PubMed ID: 15730127
    [No Abstract]   [Full Text] [Related]  

  • 16. Consumer usage patterns of nonprescription histamine2-receptor antagonists.
    Shi CW; Gralnek IM; Dulai GS; Towfigh A; Asch S
    Am J Gastroenterol; 2004 Apr; 99(4):606-10. PubMed ID: 15089889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Habit, prejudice, power and politics: issues in the conversion of H2-receptor antagonists to over-the-counter use.
    Hunt RH
    CMAJ; 1996 Jan; 154(1):49-53. PubMed ID: 8542566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roxithromycin induced hypersensitivity pneumonitis.
    Chew GY; Hawkins CA; Cherian M; Hurwitz M
    Pathology; 2006 Oct; 38(5):475-7. PubMed ID: 17008299
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost impact of switching histamine(2)-receptor antagonists to nonprescription status.
    Furler MD; Rolnick MS; Lawday KS; Mak MW; Einarson TR
    Ann Pharmacother; 2002; 36(7-8):1135-41. PubMed ID: 12086543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple eruptive keratoacanthoma and immunity disorders.
    Dangoisse C; Meyvisch K; Ledoux M
    Dermatology; 1993; 186(4):313-6. PubMed ID: 8099819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.